KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

RNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the ...

While mRNA vaccines trigger potent initial immune responses, emerging data suggest they do not generate durable plasma cells, ...

The mRNA technology that helped end the COVID-19 pandemic may now hold the key to defeating cancer, and it exists because of ...

A new preclinical study shows that mRNA delivered through lipid nanoparticles can trigger local antibody production in muscle ...

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional ...

To accurately gauge a vaccine’s risks, it is also crucial to compare its side effects with the effects of the illness it ...

CDMOs have become structural pillars of drug development, keeping pipelines moving, absorbing operational shocks, and turning ...

Vinay Prasad’s memo makes alarming claims about the COVID-19 vaccine — including the assertion, made without any supporting ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...